Medexus Pharmaceuticals Inc. MDP.TO
TSX
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 17.62% | 16.13% | -0.41% | -15.56% | -5.94% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.62% | 16.13% | -0.41% | -15.56% | -5.94% |
| Cost of Revenue | 21.90% | 21.86% | -9.68% | -28.33% | -19.32% |
| Gross Profit | 15.34% | 13.11% | 5.83% | -5.66% | 3.18% |
| SG&A Expenses | 11.63% | 6.77% | -13.02% | 2.23% | 23.00% |
| Depreciation & Amortization | -0.49% | -0.54% | 0.82% | 38.04% | 54.06% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.47% | 11.39% | -8.18% | -9.77% | 3.99% |
| Operating Income | 47.61% | 148.71% | 671.38% | -55.70% | -59.68% |
| Income Before Tax | 474.01% | -18.54% | -296.31% | -49.32% | 43.72% |
| Income Tax Expenses | 3,516.67% | -143.43% | -61.65% | 148.98% | 98.26% |
| Earnings from Continuing Operations | 358.10% | 5.43% | -383.73% | -89.09% | -386.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 358.10% | 5.43% | -383.73% | -89.09% | -386.36% |
| EBIT | 47.61% | 148.71% | 671.38% | -55.70% | -59.68% |
| EBITDA | 18.99% | 38.19% | 98.24% | -25.97% | -28.10% |
| EPS Basic | 364.29% | 6.88% | -342.78% | -91.58% | -317.78% |
| Normalized Basic EPS | 2,530.00% | 1,860.00% | 94.98% | -61.43% | -102.09% |
| EPS Diluted | 359.00% | 6.88% | -342.78% | -91.58% | -332.56% |
| Normalized Diluted EPS | 2,530.00% | 1,860.00% | 94.98% | -61.43% | -102.16% |
| Average Basic Shares Outstanding | -2.65% | -1.33% | 9.08% | 31.42% | 31.53% |
| Average Diluted Shares Outstanding | -2.65% | -1.33% | 9.08% | 31.42% | 27.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |